DELAYED TIME TO FIRST AND SUBSEQUENT EXACERBATIONS INDEPENDENT OF SEASON WITH INDACATEROL/GLYCOPYRRONIUM COMPARED WITH SALMETEROL/FLUTICASONE: THE FLAME STUDY

被引：0
|
作者：
Banerji, D. [1 ]
Chapman, K. [2 ]
Kostikas, K. [3 ]
Olsson, P. [4 ]
Thach, C. [1 ]
Patalano, F. [3 ]
Fogel, R. [1 ]
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] Univ Toronto, Univ Hlth Network, Dept Med, Asthma & Airway Ctr, Toronto, ON, Canada
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novartis Sverige AB, Taby, Sweden
来源：
RESPIROLOGY | 2018年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
TP 099
引用
收藏
页码：157 / 157
页数：1
相关论文
共 50 条
  • [1] Delayed time to first and subsequent exacerbations independent of season with indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone (SFC): the FLAME study
    Chapman, Kenneth
    Kostikas, Konstantinos
    Olsson, Petter
    Thach, Chau
    Patalano, Francesco
    Fogel, Robert
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [2] Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study
    Wedzicha, Jadwiga
    Chapman, Kenneth
    FowlerTaylor, Angel
    Ayers, Tim
    Thach, Chau
    Olsson, Petter
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [3] Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study
    Wedzicha, Jadwiga A.
    Zhong, Nanshan
    Ichinose, Masakazu
    Humphries, Michael
    Fogel, Robert
    Thach, Chau
    Patalano, Francesco
    Banerji, Donald
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2017, 12 : 339 - 349
  • [4] Indacaterol/Glycopyrronium Reduces Moderate or Severe Exacerbations Compared With Salmeterol/Fluticasone, Irrespective of Number of Exacerbations in Previous Year: Indirect Comparison From FLAME and LANTERN Studies
    Yadao, Anthony
    Fogel, Robert
    Ayers, Tim
    Thach, Chau
    Patalano, Francesco
    Banerji, Donald
    CHEST, 2016, 150 (04) : 1317A - 1317A
  • [5] SAFETY OF INDACATEROL/GLYCOPYRRONIUM (IND/GLY) COMPARED WITH SALMETEROL/FLUTICASONE (SFC) IN MODERATE-TO-VERY SEVERE COPD PATIENTS WITH PRIOR EXACERBATIONS: RESULTS FROM THE FLAME STUDY
    Wedzicha, J.
    Vestbo, J.
    Larbig, M.
    Fogel, R.
    Thach, C.
    Patalano, F.
    Banerji, D.
    RESPIROLOGY, 2016, 21 : 181 - 181
  • [6] Improvement In Sgrq Component Score With Indacaterol/glycopyrronium Versus Salmeterol/fluticasone: Results From The Flame Study
    Wedzicha, J. A.
    Chapman, K. R.
    Vogelmeier, C. F.
    Fucile, S.
    Yadao, A.
    Ayers, T.
    Thach, C.
    Taylor, A. Fowler
    Fogel, R.
    Patalano, F.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [7] IMPROVEMENT IN SGRQ COMPONENT SCORE WITH INDACATEROL/GLYCOPYRRONIUM VERSUS SALMETEROL/FLUTICASONE: RESULTS FROM THE FLAME STUDY
    Wedzicha, Jadwiga A.
    Chapman, Kenneth R.
    Vogelmeier, Claus F.
    Fucile, Sebastian
    Yadao, Anthony
    Ayers, Tim
    Thach, Chau
    Fowlertaylor, Angel
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    RESPIROLOGY, 2017, 22 : 176 - 177
  • [8] Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population
    Bjermer, Leif
    van Boven, Job F. M.
    Costa-Scharplatz, Madlaina
    Keininger, Dorothy L.
    Gutzwiller, Florian S.
    Lisspers, Karin
    Mahon, Ronan
    Olsson, Petter
    Roche, Nicolas
    RESPIRATORY RESEARCH, 2017, 18
  • [9] Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population
    Leif Bjermer
    Job F. M. van Boven
    Madlaina Costa-Scharplatz
    Dorothy L. Keininger
    Florian S. Gutzwiller
    Karin Lisspers
    Ronan Mahon
    Petter Olsson
    Nicolas Roche
    Respiratory Research, 18
  • [10] Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study
    Roche, Nicolas
    Olsson, Petter
    Vestbo, Jorgen
    FowlerTaylor, Angel
    Ayers, Tim
    Thach, Chau
    Clerkin, Karyn
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
12345